Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 1;34(6):550-554.
doi: 10.1097/ICU.0000000000000968. Epub 2023 Apr 27.

Update on pharmacotherapy for dry eye

Divya Manohar  1   2 , Roni M Shtein  1
Affiliations
Review

Update on pharmacotherapy for dry eye

Divya Manohar et al. Curr Opin Ophthalmol. .

Abstract

Purpose of review: This review provides an overview of pharmacologic treatments for dry eye disease (DED), with a focus on newer developments.

Recent findings: Along with the existing treatments, there are several new pharmacologic treatments available and being developed for DED.

Summary: There are many currently available options for treatment of DED, and ongoing research and development to expand potential treatments for patients with DED.

PubMed Disclaimer

References

    1. Labetoulle M, Benitez-Del-Castillo JM, Barabino S, et al. Artificial tears: biological role of their ingredients in the management of dry eye disease. Int J Mol Sci 2022; 23:2434.
    1. Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci 2020; 24:8642–8652.
    1. Favre H, Lahoti S, Issa N, et al. Topical steroids in management of dry eye disease. Curr Ophthalmol Rep 2020; 8:195–200.
    1. Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol 2020; 14:4187–4200.
    1. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology 2017; 124:53–60.

LinkOut - more resources